Responses
Clinical and epidemiological research
Extended report
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Compose a Response to This Article
Other responses
No responses have been published for this article.